




PHARMACEUTICAL 2022

GlobeStar Therapeutics Corp
Rank 465 of 466





PHARMACEUTICAL 2022

GlobeStar Therapeutics Corp Rank 465 of 466

The relative strengths and weaknesses of GlobeStar Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GlobeStar Therapeutics Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 348% points. The greatest weakness of GlobeStar Therapeutics Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 2,828% points.

The company's Economic Capital Ratio, given in the ranking table, is -2,996%, being 3,074% points below the market average of 78%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	6.0	Assets	6.0
Cost of Goods Sold	2.4	Liabilities	732
Intangible Assets	0	Expenses	9,802
Liabilities, Current	732	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	-726
Other Assets	0	Net Income	-9,802
Other Compr. Net Income	0	Comprehensive Net Income	-9,802
Other Expenses	707	Economic Capital Ratio	-2,996%
Other Liabilities	0		
Other Net Income	0		
Other Revenues	0		
Property and Equipment	0		
Research and Development	0		
Selling, General and Administrative Expense	9,092		